Lupin launches novel fixed-dose triple drug combination DIFIZMA DPI to treat uncontrolled asthma

5 Jan 2023 , 02:49 PM

Global pharma major Lupin Limited on Thursday has announced the launch of a novel fixed-dose triple drug combination (FDC) of Indacaterol, Glycopyrronium and Mometasone for managing inadequately controlled asthma amongst patients. 

Lupin has launched this important product under the brand name DIFIZMA in India.

Pharma-major Lupin is the first company in India to offer this novel FDC dry powder inhalation (DPI) product combining Indacaterol, a long-acting beta-agonist, Glycopyrronium, a long-acting muscarinic receptor antagonist, and Mometasone Furoate, an inhaled corticosteroid.

According to the said filing, DIFIZMA is the only FDC that has been approved by the Drug Controller General of India (DCGI) for the treatment of inadequately controlled Asthma. DIFIZMA will help in the management of inadequately controlled asthma by improving lung function, providing better symptom control and reducing exacerbations. The drug will be available in one strength with a fixed-dose to be taken once daily. 

The estimated national burden of asthma in India is at 17.23 million with an overall prevalence of 2.05%. Out of this, approximately 30 lakh patients can be classified under “inadequately controlled”. 

These are the patients who have uncontrolled symptoms and higher chances of exacerbations which may lead to hospitalization contributing to higher DALYs (Disability adjusted life years) in most patients.

At around 2:52 PM, Lupin was trading at Rs742.50 per share higher by 1.29% on the BSE.

For feedback and suggestions, write to us at [e-mail]